# Kojin Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kojin-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.kojintx.com
- Total disclosed funding: $30M
- Latest round: Series A (Jun 2, 2021)
- Investors on record: 8

## About

Founded in 2020 and based in Massachusetts, US, Kojin Therapeutics, Inc. operates as a biotechnology company that focuses on oncology and cell state biology. The company was co-founded by Benjamin Cravatt, Stephanie Dougan, Stuart L. Schreiber, and Vasanthi Viswanathan. In June 2021, Kojin Therapeutics raised USD 60 million in Series A funding co-led by Cathay Capital, Newpath Partners, and Polaris Partners.

The company’s technology is ferroptosis-based drug discovery, which is to say, iron-dependent cell death. Kojin develops therapies for hard-to-treat diseases, which include drug-resistant cancers, involve diseased cells that are sensitive to ferroptosis. Kojin’s technology platform leverages a novel non-genetic classification of cell states that allows them to understand how a cell responds to its environment and to a specific compound or molecule. It finds specific drug targets by connecting complex cell states to known biochemical processes, such as ferroptosis.

The company plans to use its funding from June 2021 to accelerate its drug discovery platform based on its proprietary approach to cell state and ferroptosis biology and its pipeline of therapeutics, with an initial focus on oncology.

## Funding rounds

- Series A, Jun 2, 2021, $30M — Polaris Partners, Alexandria Venture Investments, Cathay Capital, Eventide Asset Management, AbbVie, Cathay Capital, Newpath Partners, Leaps by Bayer, Binney Street Capital

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Cathay Capital — Series A
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series A
- AbbVie — Series A
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A
- Binney Street Capital (https://capitalatlas.ai/funds/binney-street-capital) — Series A